Needham downgraded TransMedics (TMDX) to Hold from Buy without a price target The firm’s channel checks indicate TransMedics is facing intensifying competition from a variety of directions including OrganOx, Paragonix Technologies and normothermic regional perfusion. The company’s sequential growth has slowed and this points to slower growth in 2025, the analyst tells investors in a research note. Needham believes TransMedics’ 2025 consensus estimates are likely too high and expects further downward revisions combined with additional multiple compression to weigh on the shares.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics price target lowered to $110 from $180 at Piper Sandler
- TransMedics price target lowered to $104 from $109 at Canaccord
- TransMedics price target lowered to $120 from $175 at TD Cowen
- TransMedics Group call volume above normal and directionally bullish
- McDonald’s, Ford, Pfizer report Q3 earnings beats: Morning Buzz